{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"7.310","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"1,804,439,838","primaryexch":"香港交易所","ric":"2157.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BNZFHP4","am":"107.74","iv":"","ew_strike":"","as":"7.010","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"7.000","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"1,000","update_time":"2025-09-28 00:06:03.0","lo52":"2.260","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"蒲忠傑","underlying_ric":"2157.HK","hi52":"10.500","issuer_name":"樂普生物科技股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"6.850","mkt_cap":"12.64","f_aum_hkd":null,"ew_sub_per_to":"","ls":"7.010","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.220","aum":"","issued_shares_class_B":null,"vo":"15.30","secondary_listing_flag":false,"listing_date":"2022年2月23日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"樂普生物科技股份有限公司 - B - H股","nm_s":"樂普生物－Ｂ","sym":"2157","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"樂普生物科技股份有限公司是一家主要從事銷售醫藥產品及新藥研發的公司。該公司聚焦於腫瘤治療領域，尤其是靶向治療及免疫治療。該公司致力於通過抗体药物偶联物（ADC）技術開發平台開發創新型ADC，填補癌症患者的臨床需求缺口。該公司臨床階段候選藥物包括靶向療法藥物及一種免疫治療藥物，它屬於一種溶瘤病毒藥物。","op":"7.230","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國<br/>上海市閔行區<br/>蘇召路1628號<br/>1幢C280室","pc":"-3.04","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"7.230","isin":"CNE100004SM4","moneyness":""}},"qid":"1759074146330"}
